Title: Laboratory validation of an RNA/DNA hybrid tagmentation based mNGS

workflow on SARS-CoV-2 and other respiratory RNA viruses detection

Authors: Feili Wei[a,b,#], Yanhua Yu[c,#], Zhongjie Hu[e,#], Rui Wang[d], Xianghua Guo[a,b],

Haiying Jin[c], Shan Guo[a,b], Yabo Ouyang[a,b], Ying Shi[a,b], Ronghua Jin[a,b], Dexi Chen[a,b,*]

Affiliations:

[a] Beijing Institute of Hepatology, Beijing Youan Hospital, Capital Medical University, ,

Beijing, 100069, China

[b] Beijing Precision Medicine and Transformation Engineering Technology Research

Center of Hepatitis and Liver Cancer, Beijing, 100069, China

[c] Clinical Laboratory Center, Beijing Youan Hospital, Capital Medical University,

Beijing, 100069, China

[d] Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University,

Beijing, 100069, China

[e] Department of Critical Care Medicine of Liver Disease, Beijing Youan Hospital, Capital

Medical University, Beijing, 100069, China

[#] These authors contributed equally to this work.

R. J and D. C contributed equally to this work.

*Corresponding author: D. Chen (dexichen@ccmu.edu.cn).

Abstract

Background: Acute respiratory infection (ARI) caused by RNA viruses is still one of the

main diseases all over the world such as SARS-CoV-2 and Influenza A virus. mNGS was

a powerful tool for ethological diagnosis. But there were some challenges during mNGS

implementation in clinical settings such as time-consuming manipulation and lack of

comprehensive analytical validation.

Methods: We set up CATCH that was a mNGS method based on RNA and DNA hybrid

tagmentation via Tn5 transposon. Seven respiratory RNA viruses and three subtypes of

Influenza A virus had been used to test CATCH's capabilities of detection and semi-

quantification. Analytical performance of SARS-CoV-2 and Influenza A virus had been

determined with reference standards. We compared accuracy of CATCH with quantitative

real time PCR by using clinical 98 samples from 64 COVID-19 patients.

Results: We minimized the library preparation process to 3 hours and handling time to 35

minutes. Duplicate filtered RPM of 7 respiratory viruses and 3 Influenza A virus subtypes

were highly correlated with viral concentration (r=0.60, p<0.001, Spearman correlation

test). LOD of SARS-CoV-2 was 39.2 copies/test and of Influenza A virus was 278.1

copies/mL Comparing with qR-TPCR, the overall accuracy of CATCH was 91.4%.

Sensitivity was 84.5% and specificity was 100%. Meanwhile, there were significant

difference of microbial profile in oropharyngeal swabs among critical, moderate patients

and healthy controls (p<0.001, PERMANOVA test).

Conclusion: Although further optimization is needed before CATCH can be rolled out as

a routine diagnostic test, we highlight the potential impact of it advancing molecular

diagnostics for respiratory pathogens.

Key words: RNA viruses, COVID-19, mNGS, Tn5 transposon, analytical validation

Background

Respiratory tract infection, as a global burden on public health, has caused extensive

morbidity and mortality worldwide in the past decades. It is 3rd leading causes of death

among all ages by 2015[1]. In most cases of severe acute respiratory tract infections, RNA

viruses are pathogenic agents[2-4]. For example, the novel coronavirus SARS-CoV-2,

which is pathogen of COVID-19, has caused over 3 million people infected and

thousands death from December 2019 until now[5,6]. Traditional nucleotide analysis

methods for RNA viruses, such as quantitative reverse transcription PCR (qRT-PCR), are

sensitive and specific, but only focused on pre-defined species or subtypes.

Metagenomic next-generation sequencing (mNGS), which is well studied on pathogen

detection recently, offers a culture-free and nucleotide sequence independent method that

eliminates the need to define the targets for diagnosis beforehand[7]. However, most of

those protocols have time-consuming steps and complicated manipulation including RNA

extractions,   reverse   transcription,   second-strand   complementary   synthesis,

preamplification/isothermal amplification, adapter ligation and PCR amplification. It not

only takes a long time to wait for diagnostics results but also not easy for clinician to use

in a large scale. Bacterial transposase Tn5 has been employed in next generation

sequencing by cutting double-stranded DNA (dsDNA) and ligate the resulting DNA ends

to specific adaptors[8-10]. It has been successfully used in mNGS for pathogen detection in

low input specimens[11]. Furthermore, it also can skip second-strand complementary

synthesis by direct tagmentation of RNA/DNA hybrids in scRNA-seq and SARS-CoV-

2[12-14.] But the lack of method standardization and validation of these workflows

encumbers the ability to assess the variability of results generated by different

laboratories, leading to uncertainty in the results[7,11,15,16]. Hence, laboratory validation

including low limit of detection (LOD), precision, stability, effects of interference and

accuracy for RNA viruses in one single assay is essential for implementation of mNGS

for routine pathogen detection in clinical diagnostic laboratories.

In this study, we optimized metatranscriptomic protocol based on RNA/DNA hybrid

tagmentation for detecting respiratory RNA viruses. We call this method as **CATCH**

(pathogeni**C** rn**A**/dna hybrid **T**agmentation te**CH**nology). We aimed to build up a rapid

and accurate method for mNGS to be used as a broad diagnostic tool for viral respiratory

diseases with the potential for pan-pathogen detection. Despite validation of laboratory

performance, we also determined its sensitivity and accuracy compared to that of existing

diagnostics method–qRT-PCR, using clinical samples from hospital patients during these

COVID-19 pandemic. Further optimization is needed before CATCH can be rolled out as

a routine diagnostic test, but we highlight the potential impact of it advancing molecular

diagnostics for respiratory pathogens.

Methods

CATCH workflow for respiratory RNA viruses detection

RNA was extracted using QIAamp Viral RNA Mini Kit (Qiagen, Cat.No. 52904)

following the manufacturer's instructions. Internal RNA controls, consisting of an RNA

phage (Escherichia coli bacteriophage MS2, ATCC15597-B1, Hecin Scientific, Inc), was

added into all the samples before RNA extraction at a concentration of 1×10^3 copies/mL,

in approximately 10-fold of its LOD[11]. DNA was then removed through Denature buffer

and DNase in Repli-g WTA kits (Qigen, Cat.No.150063). After removal of the DNA,

RNA/DNA hybrids were synthesis by SuperScript[TM] IV First-Strand Synthesis System

(Thermo Fisher, Cat.No. 18091050). RNA/DNA hybrids tagmentation and indexing-PCR

protocol are optimized according to Nextera XT DNA Library Prep Kit (Illumina,

Cat.No. lFC-131-1096, Supplementary Protocol). For pooling, each library was

quantified individually using the Qubit dsDNA HS Assay Kit (Thermo Fisher, Cat.No.

Q32851), followed by combining equimolar concentrations of DNA libraries. The size

distribution of the combined pools was determined using the High Sensitivity DNA kit

(Agilent, Cat.No. 5067-5583) on an Agilent 4200 Bioanalyzer. Library pools were then

sequenced on Illumina NextSeq 500 platform with SE (Single-End) 75 cycles sequencing

strategy to generate a minimum of 10~20 million reads for each library.

Bioinformatics workflow and data processing

We first used software fastp[17] (v0.19.5) to filter low-quality reads and remove adapter

with parameters: -q 20 -c -l 50), low complexity reads removal by Komplexity (-F, -k 8, -t

0.2,   version: Nov-2019),   host   removal   by   bmtagger

ftp://ftp.ncbi.nlm.nih.gov/pub/agarwala/bmtagger), and ribosomal reads

removal by SortMeRNA[18] (version:2.1b). Next, we applied Kraken2[19] (version 2.0.8-

beta, parameters: --threads 24 --confidence 0.2) to assign microbial taxonomic

assignment against the large NT reference database (version: Nov-2019) combining with

current SARS-CoV-2 reference genome (accession ID: NC_045512.2). Duplicate filtered

RPM of each virus were calculated by the follow steps: 1) Extracting reads annotated as

targeted viral species except for SARS-CoV-2. 2) Aligning all reads to targeted reference

genome with tblastx[20] (-max_target_seqs 1 -max_hsps 1 -evalue 1e-5, version:).

Alignment with beyond 90% identity of reference sequence and 90% length of query

reads are considered. 3) Reads with same start position were marked as duplicated reads

and discarded. Rest of reads were used to calculate RPM (reads per millions) by

normalizing sequencing data size. For SARS-CoV-2, reads belong to *Betacoronavirus* are

extracted. Reference sequences of all *Betacoronavirus* were used for blastn[20] alignment (-

max_target_seqs 1 -max_hsps 1 -evalue 1e-5, version:). Best hits of SARS-CoV-2 have

been kept for following analysis. The following steps were same with other viruses. For

classification of Influenza A virus subtypes, TAEC[21] had been used with default

parameter and influenza viruses database from NCBI[22]. We defined positive detection of

bacteria, fungus and viruses by the following threshold criteria: 1) more than 3 non over

lapping reads from distinct genomic regions for viruses; 2) 10-fold higher duplicate

filtered RPM than NTC. The rest of microbial taxon were considered as contamination

and discarded.

Study design of Respiratory RNA viral species and subspecies detection by CATCH

To study the performance of CATCH on detection of respiratory RNA viral species and

subspecies, we designed a panel with two Reference Standards kit. The SARS-COV-2

Standard (Lot No. GBW(E)091090) was donated by the National Institute of Metrology,

China and the 2nd National Reference Panel for Influenza A Viral Nucleic Acids

Detection Kit (Lot No.370051-201801) was acquired from the National Institutes for

Food and Drug Control, China.   In brief, all of 7 Respiratory RNA viruses and 3

Influenza A virus subspecies standard reference were first tested its highest dilution fold

(similar with LOD) except for SARS-CoV-2 and Influenza A virus (A/2009/H1N1)

which had exact viral concentrations. We defined these concentrations as baseline for the

other 6 RNA viruses and 2 Influenza A virus subspecies. For each virus or subspecies, we

improved its concentration to 10-fold comparing with baseline. Each trial was repeated

three times. For SARS-CoV-2 and Influenza A virus (A/2009/H1N1), we set

10^2copies/test and 10^4copies/mL as baseline. Each trial was repeated three times.

Evaluation of analytical performance characteristics

1) limit of detection: SARS-COV-2 RNA standard was spiked into RNA extracted from

oropharyngeal swabs VTM matrix of asymptomatic donors at concentrations ranging

from 10 to 10^4 copies/test. Influenza A virus (A/2009/H1N1) reference standard was

spiked into oropharyngeal swabs VTM matrix at concentrations ranging from 10^2 to 10^5

copies/mL. LOD were calculated in R (version 3.5.1) using probit regression analysis[23]

following approved guidelines of clinical and laboratory standards institute with 3 to 20

replicates performed at each concentration. **2) Precision:** External PC and NTC samples

were analyzed over 5 independent mNGS runs (inter-run reproducibility) and as 3

independent sets over 1 run (intra-run reproducibility) and evaluated for quality control

metrics and viral detection using established thresholds. **3) Interference:** to evaluate the

effect of human host background on mNGS assay performance, we spiked SARS-COV-2

and Influenza A virus (A/2009/H1N1) standards into low (1 x 10^4 cells/mL), medium

($1x10^5$ cells/mL), and high ($1x10^6$ cells/mL) titers of human A549 cell. **4) Stability:** to

assess stability, 3 replicates of external PC were placed in a refrigerator at 4℃ for 0, 3

and 6 days. After these manipulations, mNGS libraries were generated from the samples

and sequenced.

Patients and clinical samples

Residual RNA samples from patients at Beijing Youan Hospital with laboratory

confirmed COVID-2019 (diagnosed by qRT-PCR) and those with suspected COVID-

2019 but testing negative. 64 patients were enrolled in this study according to the 7th

guideline for the diagnosis and treatment of COVID-19 from the National Health

Commission of the People's Republic of China. Residual RNA samples (n=98) were

stored at Youan prior to testing. mNGS test results were compared to qRT-PCR testing

results. Sensitivity and specificity of the mNGS assay were calculated relative to prior

qRT-PCR test. Moreover, oropharyngeal swabs from 15 healthy volunteers were

collected and used as healthy controls.

qRT-PCR assays

We performed qRT-PCR assay using the ABI ViiA7 (Applied Biosystems) instrument

according to the CDC EUA-approved protocol. SARS-CoV-2 was detected with the

following primers: For N gene, the forward 5'CACATTGGCACCCGCAATC3', reverse

5'GAGGAACGAGAAGAGGCTTG3' and the probe fam-

5'ACTTCCTCAAGGAACAACATTGCCA3'-BHQ1. For ORF1ab gene, the forward 5'

GTGARATGGTCATGTGTGGCGG3', reverse 5'

CARATGTTAAASACACTATTAGCATA3' and the probe VIC-

5'CAGGTGGAACCTCATCAGGAGATGC3'-BHQ1[24]. All oligos and probes were

acquired from Sangon Shanghai.

Statistical analysis

Mann Whitney U test or Kruskal Wallis rank sum test was used for continuous variables

that do not follow a normal distribution. A comparison of microbiota was done by Perm-

ANOVA test. Spearman method was used for correlation test between Ct values/viral

concentration and duplicate filtered RPM.

Ethics statement

This study was reviewed and approved by the Ethics Committee of Beijing Youan

Hospital, Capital Medical University.

Conflict of interest

The authors declare no conflict of interest.

Funding

This work was supported by the COVID-19 Key Technology Research and Development

Funding of Beijing Hospital Authority, National Science and Technology Major Special

Program of the 13th Five-Year Plan (2018ZX10732202-004-003), and Beijing institute of

Hepatology Reform and Development Project (Y-2020HZ-2).

Acknowledgement

We thank Dr. Bin Yang and Mr. Peizhi Li at Illumina China for providing a

comprehensive suggestion on this project and assistance of high-throughput sequencing.

The SARS-COV-2 Standard (Lot No. GBW(E)091090) was donated by the National

Institute of Metrology, China.

Data available

The raw sequence data of samples in this study, after removal of human reads, will be

deposited to Genome Warehouse in National Genomics Data Center and the sequence

Read Archive database.

Author contribution

D. C, Z. H and R. J conceived the project; R.W, X. G, H. J and S. G conducted

experiments; Y. O.Y, Y. S and Y. Y analyzed the data; F. W wrote the manuscript with

the help from all other authors.

Results

CATCH workflow for clinical RNA viruses detection

To further adaptation of clinical uses, we minimized mNGS library preparation time and

steps by upgrading reverse transcriptase from Superscript III to Superscript IV (Thermo

Fisher), combing extension and adaptor-PCR in one step and reducing PCR extension

time within each cycle. We minimized the total time on library preparation to 3 hours and

on-hands time to 35 min (Supplementary Protocol, Figure 1A). For confirmation of this

workflow on RNA viruses detection, we tested 7 respiratory RNA viruses which were

common in CAP patients including SARS-CoV-2, Influenza A virus (A/2009/H1N1),

Influenza B virus (B/Vitoria), respiratory syncytial virus, parainfluenza virus, mumps

virus and rubella virus. All 7 RNA viruses were detected though this workflow (Figure

1B). Except for exploring targeted virus detected or not, we also tested performance of

our workflow on semi-quantification of each RNA virus by increasing concentration of

each virus to ten times comparing with baseline separately and calculating fold-change of

duplicate filtered RPM (Methods). We assumed that we could observe a significant

increase of viral signals in mNGS assay if our workflow can quantitatively measure

concentration of RNA viruses in spike-in samples. The fold-change of duplicate filtered

RPM are expected to be 10X. If then it indicates a strong capability for quantification of

our workflow. We found that viral signals of these 7 RNA viruses were ranged from

0.18[0.04, 0.33] to 177.06[141.03, 213.09] as baseline and fold-change comparing with

baseline were ranged from 5.76[2.96, 8.55] to 19.05[9.82, 28.29] (Table 1). As we

thought, all of 7 RNA viruses had a significant fold change in its own trials and duplicate

filtered viral RPM generated by CATCH are significantly correlated with viral

conentraion (r=0.60, p=7.83e-16). However, parainfluenza virus and mumps rubulavirus

showed a lower fold change than expectation (Mann Whitney U test, p=0.029 and

p=0.022), while rubella virus showed significantly higher fold-change than expectation

(Mann Whitney U test, p=0.049, Figure 1B). Further, to explore the performance of

distinguishing and quantifying related sub-species, we tested three important subtype of

Influenza A virus: pandemic A/2009/H1N1, A/H3N2 and A/H7N9. All these three

influenza A viruses can be detected. However, except for H3N2, the other two subtypes

had lower fold change of duplicate filtered RPM than our expectation (Mann Whitney U

test, p=0.002, p=0.29 and p<0.001, Figure 1C, Table 1).

Analytical performance of Influenza A virus and SARS-CoV-2

To calculate 95% limits of detection (LOD), defined as the lowest concentration at which

95% of positive samples were detected, we evaluated SARS-CoV-2 and Influenza A virus

separately at 5 different concentration levels, testing three to 20 replicates at each

concentration. From 10^5 copies/mL to 500 copies/mL library produced

2,163.00[1,093.23, 3,224.10] duplicate filtered RPM mapping to Influenza A virus. For

SARS-CoV-2, we got 1,533.67[1,015.48, 2,049.86] to 11[6.03, 15.97] duplicate filtered

RPM from 10^4 copies/test to 50 copies/test (Figure S1A and B). Across the dilution

series, duplicate-filtered RPM of both viruses were strongly associated with viral copies

or titers (Spearman Correlation Test, p=1.41e10^{-11} and p=2.12e10^{-11}). Using probit

regression analysis, a 95% limit of detection is determined for SARS-CoV-2 and

Influenza A virus (Table 2). Further, we evaluated the effects of interference from host

cell on mNGS assay performance. Host cell at a level of more than 10^5 cells /mL resulted

in a significant reduction in number of IC and virial signals of Influenza A virus

comparing with no additional host cell (Mann Whitney U test, p=0.06, p=0.04 and 0.03,

Figure S1C). Moreover, inter- and intra-assay reproducibility and stability of held in 4℃

for 0,3,6 days are also performed (Table 2). We did not find any significant difference

among Days 0, 3 and 6 (Mann Whitney U test, p=0.23 and p=0.53 and 0.55, Figure S1D).

Retrospective validation on swabs specimens of COVID-19 patients using qRT-PCR

and mNGS workflow

For evaluation of accuracy, a total of 98 RNA samples from 64 COVID-19 patients are

tested using both mNGS assay and qRT-PCR. SARS-CoV-2 viral signals are present in

44 mNGS positive samples in 47 dual-gene positive qPCR results. At single-gene

positive samples, 5 in 11 generated SARS-CoV-2 viral. No reads classified as SARS-

CoV-2 are obtained from mNGS assay of 40 qPCR-negative samples. Besides, there were

no other DNA or RNA viruses were considered as positive according our threshold in

these samples. Overall, CATCH showed 84.5% sensitivity and 100% specificity

compared to original clinical test results (Figure 3A). And if only consider dual-gene

positive samples, the sensitivity will increase to 93.7%. On the other hand, we found viral

duplicate filtered RPM of SARS-CoV-2 have strong correlation with Ct value of N gene

(R^2=0.754) rather than ORF1ab ((R^2=0.326, Figure 3B and C). Although it inferred that

CATCH might have 3'bias, we still found that CATCH had capability of RNA virus

detection and semi-quantifying viral copies concentration in clinical samples.

Microbial profile in COVID-19 patients and healthy control

To explore unique features of microbial profile in COVID-19 patients, we recruit another

15 healthy volunteers to collect their oropharyngeal swabs. In sum, we got

36,845.1[27,519.4, 46,170.7] microbial RPM in COVID-19 patients and

109,398.1[102,779.5, 116,016.8] microbial RPM in healthy control. Patients and healthy

control can be clustered as three groups by top 50 microbial genus (Figure S2A). Jensen-

Shannon divergence of all microbiome was used to calculate distance of three groups

(Critical, Moderate and Healthy, Figure S2B). There was significant difference between

COVID-19 patients (both critical and moderate) and healthy control (PERMANOVA test,

p < 0.001). And between critical and moderate group, we also found a difference in

microbiome of oropharyngeal swabs (PERMANOVA test, p = 0.013). To exclude batch

effects on microbial profile data, we re-classified samples according to collection date

and library preparation batches (Figure S2A). There were significant differences in

clusters grouped by collection date and library preparation batches (PERMANOVA test, p

< 0.001 and p < 0.001). But if only considering COVID-19 patients, we found less impact

of collection date and library preparation on microbial profile (PERMANOVA test, p =

0.053 and p = 0.182). We found characteristic microbial taxon in healthy control such as

Streptococcus, *Prevotella* and *Veilonella* that were common in human upper respiratory

tracts (Figure S2A). For COVID-19 patients, we also found an enrichment of

opportunistic pathogen such as *Candida* genus (Mann Whitney U test, p < 0.001, Figure

S3A and C). For further confirmation of this result, we used culture methods to detect

Candida genus via VITEK2[25]. There were 2 in 4 ICU patients that were detected

Candida genus positive.

Discussion

As of today, acute respiratory infection (ARI) caused by RNA viruses is still one of the

main diseases all over the world. According to the study of GLIMP[26], EPIC[4] and CAP-

China[27], viral CAP diagnosis was 37.2% in Asia, 23% in the United States and 39.2% in

China. To improve our capabilities of etiological diagnosis in infectious disease, mNGS

assay has been applied and studied by many researchers and is gradually developed to be

a powerful tool in the past few years[28]. However, there were some challenges had to be

overcome during mNGS implementation in clinical settings such as laborious wet-lab

manipulations and lack of analytical validation following with a standard guideline[7,28]. In

this study, we set up a rapid, ease-to-use and sensitive clinical mNGS workflow--CATCH

based on RNA/DNA hybrids tagmentation via Tn5 for respiratory RNA viruses detection.

Besides, we provide a series data of its analytical performance of SARS-CoV-2 and

Influenza A virus. To our knowledge, this is the first study that testing comprehensive

performance of mNGS method based on RNA/DNA hybrids tagmentation for pathogen

detection. We highly consider that this newfound characteristic feature of Tn5 will help

mNGS implementation in clinical settings. Thus, solid data of accuracy and robustness of

CATCH in pathogen detection are required and important for its clinical uses.

Of many mNGS workflow for pathogen detection, capability for quantification is still a

challenge for many reasons[29-31]. Although CATCH cannot provide a well-defined

linearity of quantification for RNA viral detection, we still found that viral signals

detected by CATCH (duplicate filtered RPM) are strongly correlation with viral copies

concentration or titers both in spiked trials and clinical samples (Figure 1A and B, Figure

2B and C). We considered that CATCH can be used as a semi-quantification tool for

many clinical uses and comparing with other detection methods. On the other hands,

CATCH can distinguish related species even subspecies. Identification of different

subtype of Influenza A virus are important for clinical diagnosis[32].

In analytical performance test with reference standard, we first found that limits of

detection of CATCH were 39.2 copies/test for SARS-CoV-2 and 278.1 copies/mL for

Influenza A virus. The sensitivity of Influenza A virus was at the same level of magnitude

described in previous mNGS study either at Illumina platform[11] or Nanopore platform[16].

While for SARS-CoV-2, we suggest that small genome size (three partial genomic

regions, 3kb) might be the reason that CATCH cannot achieve a sensitive result the same

as qRT-PCR[11,15]. Second, our data showed that high host background was a fairly

common limitation of mNGS. It inferred that negative findings of unbiased mNGS

methods might be less useful for excluding infection in high host background

samples[11,16]. We, third, explore accuracy of CATCH by clinical oropharyngeal swabs

during COVID-19 pandemic. CATCH showed a well compatibility with concentration of

input. Although there were 65.00% and 38.46% samples in qRT-PCR negative and

positive samples cannot be measured a definite concentration (Figure S3), we still have a

100% success in library preparation (Data not shown). The overall accuracy of CATCH

for SARS-CoV-2 detection relative to conventional qRT-PCR was 91.4%, with 84.5%

sensitivity and 100% specificity. In dual-gene qRT-PCR positive samples, sensitivity

increased to 93.7%. We suggest that integrity of viral RNA might impair pathogen

detective efficiency of CATCH. Moreover, as we knew, CATCH or other RNA/DNA

hybrid tagmentation method without optimization will have obvious 3'bias[13]. This feature

might also decrease possibility to capture viral fragments in clinical samples. For further

implementation, CATCH needs optimization for overcome this limitation. Last, we found

that CATCH can detect enrichment of opportunistic pathogen in oropharyngeal swabs of

COVID-19 patients comparing with healthy control. It indicated that we can expand

application of CATCH in fungal or bacterial detection in the near future. We also found

an interesting phenomenon that microbiome in oropharyngeal swabs among critical,

moderate patients and healthy people can be grouped in three clusters. Although we

excluded batch effects to some extent such as collection date and library preparation

batch, we still need more clinical data to confirm that there were significant difference in

microbiome of oropharyngeal swabs between COVID-19 patients and healthy people for

the reason that microbial profile might be affect by many artificial factors[33]. But it

inferred that CATCH have a strong potential on finding microbial biomarker for disease

evaluation and estimation[34-36].

In summary , technological advancements in library preparation methods, sequence

generation and computational bioinformatics are enabling quicker and more

comprehensive metagenomic analyses at cost-effectiveness level. We hope CATCH will

be a routine implementation of clinical mNGS in patient care settings.

Reference

1.   Wang HD, Naghavi M, Allen C, et al. Global, regional, and national life

expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death,

1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet

2016;388:1459-544.

2.   van Boheemen S, van Rijn AL, Pappas N, et al. Retrospective Validation of a

Metagenomic Sequencing Protocol for Combined Detection of RNA and DNA Viruses

Using Respiratory Samples from Pediatric Patients. J Mol Diagn 2020;22:196-207.

3.   Parrish CR, Holmes EC, Morens DM, et al. Cross-species virus transmission and

the emergence of new epidemic diseases. Microbiol Mol Biol Rev 2008;72:457-70.

4.   Jain S, Self WH, Wunderink RG, et al. Community-Acquired Pneumonia

Requiring Hospitalization among U.S. Adults. The New England journal of medicine

2015;373:415-27.

5.   Zhu N, Zhang DY, Wang WL, et al. A Novel Coronavirus from Patients with

Pneumonia in China, 2019. N Engl J Med 2020;382:727-33.

6.   Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory

disease in China. Nature 2020;579:265-+.

7.   Han D, Li Z, Li R, Tan P, Zhang R, Li J. mNGS in clinical microbiology

laboratories: on the road to maturity. Crit Rev Microbiol 2019;45:668-85.

8.   Adey A, Morrison HG, Asan, et al. Rapid, low-input, low-bias construction of

shotgun fragment libraries by high-density in vitro transposition. Genome Biol

2010;11:17.

9.   Hennig BP, Velten L, Racke I, et al. Large-Scale Low-Cost NGS Library

Preparation Using a Robust Tn5 Purification and Tagmentation Protocol. G3-Genes

Genomes Genet 2018;8:79-89.

10.   Picelli S, Bjorklund AK, Reinius B, Sagasser S, Winberg G, Sandberg R. Tn5

transposase and tagmentation procedures for massively scaled sequencing projects.

Genome Res 2014;24:2033-40.

11.   Miller S, Naccache SN, Samayoa E, et al. Laboratory validation of a clinical

metagenomic sequencing assay for pathogen detection in cerebrospinal fluid. Genome

Res 2019;29:831-42.

12.   Di L, Fu YS, Sun Y, et al. RNA sequencing by direct tagmentation of RNA/DNA

hybrids. Proc Natl Acad Sci U S A 2020;117:2886-93.

13.   Chen C, Li J, Di L, et al. MINERVA: A facile strategy for SARS-CoV-2 whole

genome deep sequencing of clinical samples. bioRxiv 2020:2020.04.25.060947.

14.   Lu B, Dong L, Yi D, et al. Transposase assisted tagmentation of RNA/DNA

hybrid duplexes. bioRxiv 2020:2020.01.29.926105.

15.   Carpenter ML, Tan SK, Watson T, et al. Metagenomic Next-Generation

Sequencing for Identification and Quantitation of Transplant-Related DNA Viruses. J

Clin Microbiol 2019;57:12.

16.   Lewandowski K, Xu YF, Pullan ST, et al. Metagenomic Nanopore Sequencing of

Influenza Virus Direct from Clinical Respiratory Samples. J Clin Microbiol 2020;58:15.

17.   Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ

preprocessor. Bioinformatics (Oxford, England) 2018;34:i884-i90.

18.   Kopylova E, Noe L, Touzet H. SortMeRNA: fast and accurate filtering of

ribosomal RNAs in metatranscriptomic data. Bioinformatics (Oxford, England)

2012;28:3211-7.

19.   Wood DE, Lu J, Langmead B. Improved metagenomic analysis with Kraken 2.

Genome Biol 2019;20:257.

20.   Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment

search tool. Journal of molecular biology 1990;215:403-10.

21.   Sohn MB, An L, Pookhao N, Li Q. Accurate genome relative abundance

estimation for closely related species in a metagenomic sample. BMC bioinformatics

2014;15:242.

22.   Benson DA, Cavanaugh M, Clark K, et al. GenBank. Nucleic acids research

2018;46:D41-d7.

23.   Armbruster D, Pry T. Limit of Blank, Limit of Detection and Limit of

Quantitation. The Clinical biochemist Reviews / Australian Association of Clinical

Biochemists 2008;29 Suppl 1:S49-52.

24.   Vogels CBF, Brito AF, Wyllie AL, et al. Analytical sensitivity and efficiency
comparisons of SARS-COV-2 qRT-PCR primer-probe sets. medRxiv
2020:2020.03.30.20048108.

25.   Kothalawala M, Jayaweera J, Arunan S, Jayathilake A. The emergence of non-
albicans candidemia and evaluation of HiChrome Candida differential agar and VITEK2
YST(R) platform for differentiation of Candida bloodstream isolates in teaching hospital
Kandy, Sri Lanka. BMC microbiology 2019;19:136.

26.   Radovanovic D, Sotgiu G, Jankovic M, et al. An international perspective on
hospitalized patients with viral community-acquired pneumonia. European journal of
internal medicine 2019;60:54-70.

27.   Zhou F, Wang Y, Liu Y, et al. Disease severity and clinical outcomes of
community-acquired pneumonia caused by non-influenza respiratory viruses in adults: a
multicentre prospective registry study from the CAP-China Network. The European
respiratory journal 2019;54.

28.   Chiu CY, Miller SA. Clinical metagenomics. Nature reviews Genetics
2019;20:341-55.

29.   Prachayangprecha S, Schapendonk CM, Koopmans MP, et al. Exploring the
potential of next-generation sequencing in detection of respiratory viruses. J Clin
Microbiol 2014;52:3722-30.

30.   van Boheemen S, van Rijn AL, Pappas N, et al. Retrospective Validation of a
Metagenomic Sequencing Protocol for Combined Detection of RNA and DNA Viruses
Using Respiratory Samples from Pediatric Patients. J Mol Diagn 2020;22:196-207.

31. Carpenter ML, Tan SK, Watson T, et al. Metagenomic Next-Generation

Sequencing for Identification and Quantitation of Transplant-Related DNA Viruses. J

Clin Microbiol 2019;57.

32. Ngaosuwankul N, Noisumdaeng P, Komolsiri P, et al. Influenza A viral loads in

respiratory samples collected from patients infected with pandemic H1N1, seasonal

H1N1 and H3N2 viruses. Virology journal 2010;7:75.

33. de Goffau MC, Lager S, Sovio U, et al. Human placenta has no microbiome but

can contain potential pathogens. Nature 2019;572:329-34.

34. Ren L, Zhang R, Rao J, et al. Transcriptionally Active Lung Microbiome and Its

Association with Bacterial Biomass and Host Inflammatory Status. mSystems 2018;3.

35. Clausen ML, Agner T, Lilje B, Edslev SM, Johannesen TB, Andersen PS.

Association of Disease Severity With Skin Microbiome and Filaggrin Gene Mutations in

Adult Atopic Dermatitis. JAMA dermatology 2018;154:293-300.

36. Bassiouni A, Paramasivan S, Shiffer A, et al. Microbiotyping the Sinonasal

Microbiome. Frontiers in cellular and infection microbiology 2020;10:137.

Figure Caption:

Figure 1. Schematic of RNA/DNA hybrid tagmentation workflow and its applications on

RNA viruses detection. (A) Optimization of RNA/DNA hybrid tagmentation workflow.

(B) Detection and semi-quantification of 7 typical respiratory RNA viruses. (C) Detection

and semi-quantification of 3 typical Influenza A virus subtype. IAV: Influenza A virus,

IBV: Influenza B virus, RSV: respiratory syncytial virus, PIV: parainfluenza virus,

Mumps V: mumps virus and Rubella V: rubella virus.

Figure 2. Accuracy of mNGS workflow comparing with qRT-PCR. (A) 2 X 2

contingency tables comparing the performance of mNGS workflow relative to qRT-PCR

and clinical testing. The composite qRT-PCR standards used are both gene are detected

(left), both gene negative (middle) and single gene detected (right). (B) Comparation of

qRT-PCR ORF1ab gene Ct value and mNGS viral signals. (C) Comparation of qRT-PCR

N gene Ct value and mNGS viral signals.

Figure S1. Analytical characteristics of SARS-CoV-2 Influenza A virus. (A) LOD of

SARS-CoV-2. (B) LOD of Influenza A virus. (C) Interference test with A549 host cell on

Influenza A virus and Internal control. (D) Stability test on Influenza A virus and Internal

control.

Figure S2. Microbial profile in oropharyngeal swabs of critical, moderate patients and

healthy volunteers. (A) Heatmap of Top 50 microbial genus of critical, moderate patients

and healthy volunteers. Red color represents high relative abundance and black color

represents low relative abundance. (B) PCoA of microbiome in oropharyngeal swabs. (C)

Relative abundance of *Candida genus* in different group.

Figure S3. RNA concentration of clinical oropharyngeal swabs specimens after DNase

treatment. (A) Distribution of RNA concentration of throat swabs. Points lower than LOD

of Qubit are generated by random function. (B) Proportion of samples with RNA

concentration lower than LOD of Qubit.

Table 1. Detection and quantification performance of 7 RNA viruses and 3 influenza A virus subtypes by CATCH

Viral Name	Genome Size	GC%	1X duplicate filtered RPM	10X duplicate filtered RPM	Fold-change comparing with baseline (1X)	p-value
SARS-CoV-2	3k	38.0	20.15(3.02, 37.28)	215.12(160.07, 270.16)	11.78(8.76, 14.79)	0.126
Influenza A virus (A/2009(H1N1))	13k	44.2	177.06(141.03, 213.09)	2198.24(1471.33, 2925.15)	12.41(8.31, 16.52)	0.127
Influenza B virus (B/Victoria)	14k	40.2	9.08(5.53, 12.62)	126.99(71.07, 182.92)	13.99(7.83,20.15)	0.108
Respiratory Syncytial Virus	15k	33.2	11.22(7.55, 14.88)	213.73(110.10, 317.36)	19.05(9.82, 28.29)	0.051
Parainfluenza virus	15k	37.2	12.37(5.84, 18.89)	191.04(140.71, 241.37)	15.45(11.38, 19.52)	*0.029*
Rubella virus	9.7k	69.6	17.76(12.37, 23.16)	119.89(6.49, 17.49)	6.75(3.65, 9.85)	*0.046*
Mumps rubulavirus	15k	42.5	20.05(8.38, 31.77)	165.39(59.58, 171.92)	5.76(2.96, 8.55)	*0.022*
Influenza A virus (A/2009(H1N1))	13k	44.2	4.73(3.90, 5.55)	16.49(10.46, 22.52)	3.36(2.13, 4.59)	*0.002*
Influenza A virus (A/H3N2)	13k	45.0	5.25(2.95, 7.55)	38.92(11.26, 66.58)	8.09(2.34, 13.84)	0.29
Influenza A virus (A/H7N9)	13k	45.1	1.10(0.62, 1.57)	5.36(3.08, 7.63)	1.69(0.97, 2.40)	*<0.001*

Table 2. Performance characteristics for CATCH on Influenza A virus and SARS-CoV-2

Performance metrics	Method	Results
Limits of detection	SARS-CoV-2	39.2 copies/test
	Influenza A virus (A/H1N1/2009)	278.1 copies/mL
Precision	Qualitative detection of both viruses over 5 consecutive runs	100% concordance
	Qualitative detection of both viruses over 3 replicates on the same runs	100% concordance
Stability	Qualitative detection of Influenza A virus held at 4°C for 0, 3, 6 days	100% concordance
Interference	Qualitative detection of Influenza A virus in Spiked host cell A549 (low, medium and high concentration)	Only in 10^4 cell/mL, all spiked ICs are detected above QC thresholds; All spiked Influenza A virus are detected above QC expect for 2 replicates at high concentration level